Dr. Robert J. Fox, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Johns Hopkins University School of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 42
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: Johns Hopkins University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
OH license 35078522F
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cleveland Clinic Cleveland, OH
Medical groups
- Cleveland Clinic (7,090 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 42
- Services billed
- 59
- Patients’ average age
- 65
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 21 | 19 |
| Established patient office or other outpatient visit, 30-39 minutes | 17 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Fingolimod (fingolimod hcl) | 19 |
| Glatopa (glatiramer acetate) | 19 |
| Zeposia (ozanimod hydrochloride) | 18 |
| Kesimpta Pen (ofatumumab) | 16 |
| Baclofen Other prescribers in Cleveland, OH | 13 |
| Azathioprine Other prescribers in Cleveland, OH | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 25 payments worth $55,243 in total to this clinician.
| Genzyme Corporation | $25,160 |
|---|---|
| Genentech USA, Inc. | $7,779 |
| E.r. Squibb & Sons, L.l.c. | $5,100 |
| Roche Diagnostics International LTD | $4,935 |
| Novartis Pharma AG | $3,300 |
| Biogen, Inc. | $2,863 |
| Tg Therapeutics, Inc. | $2,559 |
| Pfizer Inc. | $2,375 |
| Consulting Fee | $40,600 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $13,320 |
| Food and Beverage | $857 |
| Travel and Lodging | $466 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation May 29, 2025 | Compensation for services other than consulting (speaking, faculty) | $13,320 |
| Genzyme Corporation Oct 23, 2025 | Consulting Fee | $11,840 |
| Genentech USA, Inc. Jun 8, 2025 | Consulting Fee | $7,065 |
| Roche Diagnostics International LTD Nov 5, 2025 | Consulting Fee | $4,767 |
| Novartis Pharma AG May 28, 2025 | Consulting Fee Rhapsido · Others | $3,300 |
| Biogen, Inc. Oct 6, 2025 | Consulting Fee | $2,740 |
| Pfizer Inc. Mar 24, 2025 | Consulting Fee | $2,375 |
| Tg Therapeutics, Inc. Sep 24, 2025 | Consulting Fee BRIUMVI · Immunology | $2,363 |
| E.r. Squibb & Sons, L.l.c. Oct 8, 2025 | Consulting Fee | $2,160 |
| E.r. Squibb & Sons, L.l.c. Jan 31, 2025 | Consulting Fee | $1,500 |
All 14 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Ptc Therapeutics, Inc. Dec 1, 2025 | Consulting Fee | $1,050 |
| Roche Diagnostics International LTD Nov 5, 2025 | Consulting Fee | $4,767 |
| Genzyme Corporation Oct 23, 2025 | Consulting Fee | $11,840 |
| E.r. Squibb & Sons, L.l.c. Oct 8, 2025 | Consulting Fee | $2,160 |
| Biogen, Inc. Oct 6, 2025 | Consulting Fee | $2,740 |
| Tg Therapeutics, Inc. Sep 24, 2025 | Consulting Fee BRIUMVI · Immunology | $2,363 |
| E.r. Squibb & Sons, L.l.c. Aug 14, 2025 | Consulting Fee | $1,440 |
| Genentech USA, Inc. Jun 8, 2025 | Consulting Fee | $7,065 |
| Genentech USA, Inc. Jun 8, 2025 | Travel and Lodging travel to Dallas, TX · in-kind | $302 |
| Genentech USA, Inc. Jun 8, 2025 | Travel and Lodging travel to Dallas, TX | $164 |
| Genzyme Corporation May 29, 2025 | Compensation for services other than consulting (speaking, faculty) | $13,320 |
| Novartis Pharma AG May 28, 2025 | Consulting Fee Rhapsido · Others | $3,300 |
| Pfizer Inc. Mar 24, 2025 | Consulting Fee | $2,375 |
| E.r. Squibb & Sons, L.l.c. Jan 31, 2025 | Consulting Fee | $1,500 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $68,285 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Genzyme Corporation · Active, not recruiting · NCT06372145 - Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
Genzyme Corporation · Completed · NCT04458051 - Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)
Genzyme Corporation · Completed · NCT04411641
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.